PD-L2 is a second ligand for PD-I and inhibits T cell activation

被引:2358
作者
Latchman, Y
Wood, CR
Chernova, T
Chaudhary, D
Borde, M
Chernova, I
Iwai, Y
Long, AJ
Brown, JA
Nunes, R
Greenfield, EA
Bourque, K
Boussiotis, VA
Carter, LL
Carreno, BM
Malenkovich, N
Nishimura, H
Okazaki, T
Honjo, T
Sharpe, AH
Freeman, GJ
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Dept Adult Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Div Immunol Res, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
[4] Wyeth Ayerst Res, Genet Inst, Cambridge, MA 02140 USA
[5] Kyoto Univ, Grad Sch Med, Dept Med Chem, Kyoto 6068501, Japan
关键词
D O I
10.1038/85330
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Programmed death I (PD-1)-deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance. We identify here PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4(+) T cells,At low antigen concentrations, PD-L2-PD-1 interactions inhibit strong B7-CD28 signals, In contrast, at high antigen concentrations, PD-L2-PD-1 interactions reduce cytokine production but do not inhibit T cell proliferation. PD-L-PD-1 interactions lead to cell cycle arrest in G(0)/G(1) but do not increase cell death. In addition, ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2, as compared to TCR ligation alone, PD-L expression was up-regulated on antigen-presenting cells by interferon gamma treatment and was also present on some normal tissues and tumor cell lines,Taken together, these studies show overlapping functions of PD-L1 and PD-L2 and indicate a key role for the PD-L-PD-1 pathway in regulating T cell responses.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 24 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]   Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-γ [J].
Badovinac, VP ;
Tvinnereim, AR ;
Harty, JT .
SCIENCE, 2000, 290 (5495) :1354-1357
[3]   Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells [J].
Chambers, CA ;
Sullivan, TJ ;
Allison, JP .
IMMUNITY, 1997, 7 (06) :885-895
[4]   Failure to suppress the expansion of the activated CD4 T cell population in interferon γ-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis [J].
Chu, CQ ;
Wittmer, S ;
Dalton, DK .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (01) :123-128
[5]  
Chuang E, 1999, J IMMUNOL, V162, P1270
[6]  
Dong HD, 1999, NAT MED, V5, P1365
[7]   LOCALIZATION OF THE BINDING-SITE FOR THE HUMAN HIGH-AFFINITY FC RECEPTOR ON IGG [J].
DUNCAN, AR ;
WOOF, JM ;
PARTRIDGE, LJ ;
BURTON, DR ;
WINTER, G .
NATURE, 1988, 332 (6164) :563-564
[8]   SELECTIVE INDUCTION OF B7/BB-1 ON INTERFERON-GAMMA STIMULATED MONOCYTES - A POTENTIAL MECHANISM FOR AMPLIFICATION OF T-CELL ACTIVATION THROUGH THE CD28 PATHWAY [J].
FREEDMAN, AS ;
FREEMAN, GJ ;
RHYNHART, K ;
NADLER, LM .
CELLULAR IMMUNOLOGY, 1991, 137 (02) :429-437
[9]   Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].
Freeman, GJ ;
Long, AJ ;
Iwai, Y ;
Bourque, K ;
Chernova, T ;
Nishimura, H ;
Fitz, LJ ;
Malenkovich, N ;
Okazaki, T ;
Byrne, MC ;
Horton, HF ;
Fouser, L ;
Carter, L ;
Ling, V ;
Bowman, MR ;
Carreno, BM ;
Collins, M ;
Wood, CR ;
Honjo, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034
[10]   INDUCED EXPRESSION OF PD-1, A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY, UPON PROGRAMMED CELL-DEATH [J].
ISHIDA, Y ;
AGATA, Y ;
SHIBAHARA, K ;
HONJO, T .
EMBO JOURNAL, 1992, 11 (11) :3887-3895